[go: up one dir, main page]

NO980630L - Kjemiske forbindelser - Google Patents

Kjemiske forbindelser

Info

Publication number
NO980630L
NO980630L NO980630A NO980630A NO980630L NO 980630 L NO980630 L NO 980630L NO 980630 A NO980630 A NO 980630A NO 980630 A NO980630 A NO 980630A NO 980630 L NO980630 L NO 980630L
Authority
NO
Norway
Prior art keywords
enzyme
cpb
mutated
adept
prodrug
Prior art date
Application number
NO980630A
Other languages
English (en)
Other versions
NO980630D0 (no
Inventor
David Charles Blakey
David Huw Davies
Robert Ian Dowell
John Frederick Hennam
Peter Robert Marsham
Anthony Michael Slater
Laurent Francois And Hennequin
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9516810.0A external-priority patent/GB9516810D0/en
Priority claimed from GBGB9611019.2A external-priority patent/GB9611019D0/en
Priority claimed from GBGB9612295.7A external-priority patent/GB9612295D0/en
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of NO980630D0 publication Critical patent/NO980630D0/no
Publication of NO980630L publication Critical patent/NO980630L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Antistoff-rettet enzym promedikamentterapi (ADEPT) systemer til bruk i kreft basert på muterte karboksypeptidase B (CPB) enzymer. Enzymkonjugater til ADEPT er i hovedsak ikke immunogene hos mennesker og omfatter en målsøkende del (for eksempel et antistoff) som har evne til å binde med et tumor-assosiert antigen, der den målsøkende del er koblet til en mutert form av et CPB-enzym som har evne til å omdanne et promedikament til et anti-neoplastisk medikament, der promedikamentet ikke kan målbart overføres til et anti-neoplastisk medikament av det naturlige ikke- muterte enzym hos mennesker. En foretrukket enzym-mutant er humant CPB fra bukspyttkjertel som omfatter en Lys- eller Arg-rest i posisjon 253. Passende sennepsgass-promedikamenter blir beskrevet i spesifikasjonen.
NO980630A 1995-08-16 1998-02-13 Kjemiske forbindelser NO980630L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9516810.0A GB9516810D0 (en) 1995-08-16 1995-08-16 Chemical compounds
GBGB9611019.2A GB9611019D0 (en) 1996-05-25 1996-05-25 Chemical compounds
GBGB9612295.7A GB9612295D0 (en) 1996-06-12 1996-06-12 Chemical compounds
PCT/GB1996/001975 WO1997007769A2 (en) 1995-08-16 1996-08-13 Chemical compounds

Publications (2)

Publication Number Publication Date
NO980630D0 NO980630D0 (no) 1998-02-13
NO980630L true NO980630L (no) 1998-04-07

Family

ID=27267862

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980630A NO980630L (no) 1995-08-16 1998-02-13 Kjemiske forbindelser

Country Status (19)

Country Link
US (1) US6436691B1 (no)
EP (1) EP0844885A2 (no)
JP (1) JPH11511970A (no)
KR (1) KR19990036383A (no)
CN (1) CN1193278A (no)
AU (1) AU707689B2 (no)
BR (1) BR9610050A (no)
CA (1) CA2227040A1 (no)
CZ (1) CZ43098A3 (no)
GB (1) GB2317387B (no)
HU (1) HUP9900062A3 (no)
IL (1) IL123271A0 (no)
MX (1) MX9800967A (no)
NO (1) NO980630L (no)
NZ (1) NZ315713A (no)
PL (1) PL325017A1 (no)
SK (1) SK19498A3 (no)
TR (1) TR199800233T1 (no)
WO (1) WO1997007769A2 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2227040A1 (en) 1995-08-16 1997-03-06 Zeneca Limited Chemical compounds
GB9703201D0 (en) * 1997-02-15 1997-04-02 Zeneca Ltd Chemical compounds
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
JP2002533072A (ja) * 1998-12-21 2002-10-08 イーライ・リリー・アンド・カンパニー β−リポトロピンおよび他のペプチドの組換え合成
HUP0500423A2 (hu) * 1999-09-17 2005-08-29 Gtc Biotherapeutics, Inc. Transzgenikus úton előállított fúziós fehérjék
WO2010042654A2 (en) * 2008-10-07 2010-04-15 The Regents Of The University Of California Recombinant nell protein production
WO2006035008A1 (de) * 2004-09-27 2006-04-06 Merck Biosciences Ag Rekombinante carboxypeptidase b
AU2009271117A1 (en) * 2008-07-14 2010-01-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for predicting and detecting tumor metastasis
JP7574821B2 (ja) * 2022-03-29 2024-10-29 横河電機株式会社 複合体の製造方法、微生物の混入の有無を判別する方法及び、混入した微生物の同定を行う方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364934A (en) 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
HU190129B (en) * 1983-07-11 1986-08-28 Reanal Finomvegyszergyar,Hu Process for the isolation of carboxypeptidase b enzyme from mammal pancreas
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
GB8809616D0 (en) 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US5632990A (en) 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
AU648015B2 (en) 1989-01-23 1994-04-14 Akzo N.V. Site specific in-vivo activation of therapeutic drugs
US5433955A (en) 1989-01-23 1995-07-18 Akzo N.V. Site specific in vivo activation of therapeutic drugs
US5206161A (en) * 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
CA2127126A1 (en) 1992-01-30 1993-08-05 Helen M. Wilks Chiral synthesis with modified enzymes
US6187579B1 (en) * 1993-10-28 2001-02-13 Carlsberg A/S Customized proteases
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
US5389537A (en) 1994-01-21 1995-02-14 Wisconsin Alumni Research Foundation Nuclease having altered specificity
CA2205091A1 (en) * 1994-12-23 1996-07-04 Zeneca Limited Chemical compounds
IL116696A (en) * 1995-01-25 1999-08-17 Bio Technology General Corp Production of enzymatically active recombinant carboxypeptidase b
US5837516A (en) * 1995-03-03 1998-11-17 Genentech, Inc. Subtilisin variants capable of cleaving substrates containing basic residues
CA2227040A1 (en) 1995-08-16 1997-03-06 Zeneca Limited Chemical compounds
US5985627A (en) * 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase

Also Published As

Publication number Publication date
IL123271A0 (en) 1998-09-24
CZ43098A3 (cs) 1998-05-13
AU6747696A (en) 1997-03-19
HUP9900062A3 (en) 1999-11-29
WO1997007769A2 (en) 1997-03-06
KR19990036383A (ko) 1999-05-25
BR9610050A (pt) 1999-10-13
GB2317387B (en) 1999-08-18
AU707689B2 (en) 1999-07-15
JPH11511970A (ja) 1999-10-19
HUP9900062A2 (hu) 1999-04-28
GB2317387A (en) 1998-03-25
WO1997007769A3 (en) 1997-07-10
MX9800967A (es) 1998-11-29
CN1193278A (zh) 1998-09-16
GB9726893D0 (en) 1998-02-18
NZ315713A (en) 1999-08-30
CA2227040A1 (en) 1997-03-06
US6436691B1 (en) 2002-08-20
PL325017A1 (en) 1998-07-06
NO980630D0 (no) 1998-02-13
SK19498A3 (en) 1998-09-09
EP0844885A2 (en) 1998-06-03
TR199800233T1 (xx) 1998-06-22

Similar Documents

Publication Publication Date Title
ATE160506T1 (de) Verbesserungen an abgabesystemen für arzneimittel
NO990518D0 (no) Langtidsvirkende medikamenter og farmas°ytiske sammensetninger som omfatter disse
GR1000712B (el) Νεα αντισωματα που αντιδρουν με τα ανθρωπινα καρκινωματα.
DE69636923D1 (de) Katalytischer antikörper gegen aldolase
NO980630L (no) Kjemiske forbindelser
AU7079396A (en) Anti-galalpha(1,3)gal antibody binding peptides
WO2008089053A3 (en) Gp100-specific t cell receptors and related materials and methods of use
ATE502053T1 (de) Rekombinanter, tumorspezifischer antikörper und dessen verwendung
AU639241B2 (en) Bispecific and oligospecific mono- and oligovalent receptors, the preparation and use thereof
DE59109161D1 (de) Neue treibgase und ihre verwendung in arzneimittelzubereitungen
IL132380A0 (en) Compositions comprising conjugates of stable active human ob protein with antibody fc chain and methods
WO2020132366A4 (en) T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
WO2023137156A3 (en) T cell modulatory polypeptides with conjugation sites and methods of use thereof
Simpson et al. Killing of cultured hepatocytes by conjugates of asialofetuin and EGF linked to the A chains of ricin or diphtheria toxin
WO1993004191A1 (en) Noncytolytic toxin conjugates
CA2124217A1 (en) Inactivation of cytotoxic drugs
AU5698996A (en) Transepithelial transport of molecular species
DE60043070D1 (de) Proteine-abgabe durch polare epithelzellen schichte
NO972522L (no) Monoklonale antistoffer med immunoundertrykkende aktivitet
Marsh et al. A flexible peptide spacer increases the efficacy of holoricin anti-T cell immunotoxins.
AU2003270010A1 (en) Transferrin fusion protein libraries
WO2024227083A3 (en) Anti-ccr8 antibodies, conjugates, and uses thereof
AU8564098A (en) The ha-1 antigen
CA3266848A1 (en) ANTIBODIES, ANTIBODY-DRUG CONJUGATIONS, PREPARATIONS AND ASSOCIATED USES
AU5569600A (en) Novel protein and dna thereof